- Report
- October 2024
- 195 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Clinical Trials
- April 2024
- 107 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- May 2024
- 132 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- July 2022
- 298 Pages
Global
From €3340EUR$3,500USD£2,799GBP
- Report
- January 2022
- 200 Pages
Global
From €7158EUR$7,500USD£5,997GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- August 2022
Global
From €754EUR$790USD£632GBP
- Report
- April 2022
- 86 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Drug Pipelines
- August 2020
- 123 Pages
Global
From €1909EUR$2,000USD£1,599GBP
The Genital Herpes Drug market is a subset of the larger Infectious Diseases Drugs market. Genital Herpes is a sexually transmitted infection caused by the herpes simplex virus (HSV). Treatment for genital herpes includes antiviral medications, which can reduce the severity and duration of symptoms. These drugs can also reduce the risk of transmitting the virus to others. Commonly prescribed medications include acyclovir, valacyclovir, and famciclovir. These drugs are available in both oral and topical forms.
The Genital Herpes Drug market is highly competitive, with many companies offering similar products. Major players in the market include GlaxoSmithKline, Novartis, Merck, Pfizer, and Sanofi. Other companies include Mylan, Teva Pharmaceuticals, and Cipla. Show Less Read more
